公开(公告)号：US5445607A

公开(公告)日：1995-08-29

申请号：US962030

申请日：1992-10-15

Applicant: Srinivasan Venkateshwaran ,  Daniel C. H. Cheng

Inventor： Srinivasan Venkateshwaran ,  Daniel C. H. Cheng

IPC: A61M37/00 ,  A61N1/30

CPC classification number: A61N1/0444 ,  A61N1/0448

Abstract: An iontophoresis device comprising a drug reservoir containing the drug in ionic form and in communication with the skin, a skin permeation enhancing agent contained in the reservoir or in a second reservoir also in communication with the skin, an electrode in contact with the drug, another electrode in contact with the skin, a D.C. power source connected to the electrodes and an electrically sensitive membrane interposed between the reservoir and the skin that is impermeable to drug in the absence of a voltage difference between the electrodes and permeable to the drug in the presence of a voltage difference. The skin permeation enhancing agent eliminates the skin as a rate-controlling element, thus making the rate of drug administration dependent upon the membrane permeability, which in turn is controlled electrically.

Abstract translation: 一种离子电渗疗法装置，其特征在于，包含含有离子形式的药物并与皮肤连通的药物储存器，包含在储存器中的皮肤渗透增强剂或与皮肤相连的第二储存器，与药物接触的电极，另一种 与皮肤接触的电极，连接到电极的DC电源和插入在储存器和皮肤之间的电敏膜，其在不存在电极之间的电压差并且在存在下可渗透的药物时是不可渗透的 的电压差。 皮肤渗透增强剂消除皮肤作为速率控制元件，从而使得药物施用的速率取决于膜渗透性，其又被电控制。

公开(公告)号：US11304960B2

公开(公告)日：2022-04-19

申请号：US12350930

申请日：2009-01-08

Applicant: Chandrashekar Giliyar ,  Nachiappan Chidambaram ,  Mahesh V. Patel ,  Srinivasan Venkateshwaran

Inventor： Chandrashekar Giliyar ,  Nachiappan Chidambaram ,  Mahesh V. Patel ,  Srinivasan Venkateshwaran

IPC: A61K31/569 ,  A61K9/48 ,  A61K31/568 ,  A61K9/00 ,  A61K47/10 ,  A61K47/14 ,  A61K47/44

Abstract: Provided herein are steroid containing compositions suitable for providing therapeutically effective amounts of at least one steroid to individuals. Also provided herein are compositions comprising testosterone and/or testosterone derivatives suitable for providing therapeutically effective and safe amounts of testosterone over periods of time. Further provided are methods of treating andro- and/or testosterone deficiency in individuals by administering to the individuals compositions described herein.

公开(公告)号：US20150038475A1

公开(公告)日：2015-02-05

申请号：US14500438

申请日：2014-09-29

Applicant: Basawaraj Chickmath ,  Chandrashekar Giliyar ,  Chidambaram Nachiappan ,  Mahesh Patel ,  Srinivasan Venkateshwaran

Inventor： Basawaraj Chickmath ,  Chandrashekar Giliyar ,  Chidambaram Nachiappan ,  Mahesh Patel ,  Srinivasan Venkateshwaran

IPC: A61K9/20 ,  A61K47/10 ,  A61K47/36 ,  A61K31/568

CPC classification number: A61K9/2031 ,  A61K9/14 ,  A61K9/146 ,  A61K9/148 ,  A61K9/1652 ,  A61K9/1676 ,  A61K9/1694 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/205 ,  A61K9/2054 ,  A61K9/282 ,  A61K9/2853 ,  A61K9/286 ,  A61K9/2866 ,  A61K9/4866 ,  A61K9/4875 ,  A61K31/568 ,  A61K47/10 ,  A61K47/36 ,  A61K47/38 ,  A61K47/40

Abstract: The present disclosure is drawn to pharmaceutical compositions and oral dosage forms containing testosterone undecanoate, as well as related methods of treatment. In one embodiment, the oral dosage form can include a therapeutically effective amount of testosterone undecanoate and a pharmaceutically acceptable carrier. The dosage form can be formulated such that, when measured using a USP Type II apparatus in 1000 mL of 8 wt % Triton X-100 in water at 37° C. and 100 rpm, the oral dosage form releases at least 20% more testosterone undecanoate after the first 120 minutes than an equivalent dose testosterone undecanoate containing oral dosage form without the pharmaceutically acceptable carrier.

Abstract translation: 本公开涉及含有十一酸睾酮的药物组合物和口服剂型，以及相关的治疗方法。 在一个实施方案中，口服剂型可以包括治疗有效量的十一酸睾酮和药学上可接受的载体。 可以配制剂型，使得当使用USP II型装置在1000mL的8重量％Triton X-100在水中在37℃和100rpm下测量时，口服剂型释放至少20％以上的睾酮 十一酸十一酸酯比不含药学上可接受的载体的含有口服剂型的等效剂量十一酸睾酮。

公开(公告)号：US20150018324A1

公开(公告)日：2015-01-15

申请号：US14500498

申请日：2014-09-29

Applicant: Basawaraj Chickmath ,  Chandrashekar Giliyar ,  Chidambaram Nachiappan ,  Mahesh V. Patel ,  Srinivasan Venkateshwaran

Inventor： Basawaraj Chickmath ,  Chandrashekar Giliyar ,  Chidambaram Nachiappan ,  Mahesh V. Patel ,  Srinivasan Venkateshwaran

IPC: A61K9/28 ,  A61K47/38 ,  A61K47/10 ,  A61K9/20 ,  A61K31/568 ,  A61K47/36

CPC classification number: A61K9/2031 ,  A61K9/14 ,  A61K9/146 ,  A61K9/148 ,  A61K9/1652 ,  A61K9/1676 ,  A61K9/1694 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/205 ,  A61K9/2054 ,  A61K9/282 ,  A61K9/2853 ,  A61K9/286 ,  A61K9/2866 ,  A61K9/4866 ,  A61K9/4875 ,  A61K31/568 ,  A61K47/10 ,  A61K47/36 ,  A61K47/38 ,  A61K47/40

Abstract: The present disclosure is drawn to pharmaceutical compositions and oral dosage forms containing testosterone undecanoate, as well as related methods of treatment. In one embodiment, the oral dosage form can include a therapeutically effective amount of testosterone undecanoate and a pharmaceutically acceptable carrier. The dosage form can be formulated such that, when measured using a USP Type II apparatus in 1000 mL of 8 wt % Triton X-100 in water at 37° C. and 100 rpm, the oral dosage form releases at least 20% more testosterone undecanoate after the first 120 minutes than an equivalent dose testosterone undecanoate containing oral dosage form without the pharmaceutically acceptable carrier.

公开(公告)号：US20120322780A1

公开(公告)日：2012-12-20

申请号：US13592258

申请日：2012-08-22

Applicant: Chandrashekar Giliyar ,  Nachiappan Chidambaram ,  Mahesh V. Patel ,  Srinivasan Venkateshwaran

Inventor： Chandrashekar Giliyar ,  Nachiappan Chidambaram ,  Mahesh V. Patel ,  Srinivasan Venkateshwaran

IPC: A61K31/568 ,  A61P5/26

CPC classification number: A61K31/569 ,  A61K9/0053 ,  A61K9/4858 ,  A61K9/4866 ,  A61K9/4875 ,  A61K31/568 ,  A61K47/10 ,  A61K47/14 ,  A61K47/44

Abstract: Provided herein are steroid containing compositions suitable for providing therapeutically effective amounts of at least one steroid to individuals. Also provided herein are compositions comprising testosterone and/or testosterone derivatives suitable for providing therapeutically effective and safe amounts of testosterone over periods of time. Further provided are methods of treating andro- and/or testosterone deficiency in individuals by administering to the individuals compositions described herein.

Abstract translation: 本文提供了适用于向个体提供治疗有效量的至少一种类固醇的含甾族化合物的组合物。 本文还提供包含适于在一段时间内提供治疗有效和安全量的睾酮的睾酮和/或睾酮衍生物的组合物。 还提供了通过给予本文所述的个体组合物来治疗个体中的和/或睾酮缺乏症的方法。

公开(公告)号：US06727401B1

公开(公告)日：2004-04-27

申请号：US09022504

申请日：1998-02-12

Applicant: Srinivasan Venkateshwaran ,  Danyi Quan

Inventor： Srinivasan Venkateshwaran ,  Danyi Quan

IPC: A61F1300

CPC classification number: A61K9/7061 ,  A61F13/105 ,  A61K8/4946 ,  A61Q3/00

Abstract: A device for treating antifungal infections of toenails and fingernails is made up of an occlusive backing layer and a pressure sensitive adhesive matrix layer in which is uniformly dispersed an effective amount of an antifungal agent and, optionally, a chemical enhancer. The matrix layer has a first surface adhering to the backing layer and a second surface adapted to be in diffusional contact with the infected nail and surrounding skin area. The device is configured, when applied, to cover and adhere to the nail and surrounding skin areas for an extended period of time without causing irritation to the skin or inhibiting normal physical activity while providing a continuous delivery of antifungal agent to the infected area.

Abstract translation: 用于治疗脚趾甲和指甲的真菌感染的装置由闭塞背衬层和压敏粘合剂基质层组成，其中均匀分散有效量的抗真菌剂和任选的化学增强剂。 基质层具有粘附到背衬层的第一表面和适于与受感染的指甲和周围皮肤区域扩散接触的第二表面。 该装置在施用时被配置为在延长的时间段内覆盖并粘附到指甲和周围皮肤区域，而不会对皮肤产生刺激或抑制正常的身体活动，同时提供抗真菌剂到感染区域的连续递送。

公开(公告)号：US5780050A

公开(公告)日：1998-07-14

申请号：US504430

申请日：1995-07-20

Applicant: Uday Jain ,  Srinivasan Venkateshwaran ,  Charles D. Ebert

Inventor： Uday Jain ,  Srinivasan Venkateshwaran ,  Charles D. Ebert

IPC: A61K9/70 ,  A61K31/565 ,  A61K31/57 ,  A61K47/04 ,  A61K47/10 ,  A61K47/14 ,  A61K47/16 ,  A61K47/20 ,  A61K47/30 ,  A61K47/32 ,  A61K47/44 ,  A61P5/24 ,  A61P5/38 ,  A61F13/00

CPC classification number: A61K9/7061 ,  A61K31/568 ,  A61K31/569 ,  A61K31/57 ,  A61K31/573 ,  A61K31/575

Abstract: A stabilized patch device for transdermal drug delivery of steroid drugs containing a 3-keto-4-en functional group is described, wherein the patch comprises an effective amount of the steroid drug and a carrier that is free of acid functional groups. The device can further contain additives such as a penetration enhancer or excipient, so long as such additives are also free of acid functional groups. The device can be either a matrix patch or a liquid reservoir patch. In a matrix patch, the carrier is a biocompatible polymeric adhesive with which the steroid drug is intimately admixed. The adhesive is preferably an acrylic polymer or copolymer. In a liquid reservoir patch, the carrier is a controlled-viscosity composition containing a thinner or thickener. Preferred steroid drugs include certain corticosteroids and sex hormones, such as progestins and androgens. A method of stabilizing such steroid drugs during storage in transdermal patches is also disclosed.

Abstract translation: 描述了一种用于经皮药物递送含有3-酮-4-烯官能团的类固醇药物的稳定补片装置，其中补片包含有效量的类固醇药物和不含酸官能团的载体。 该装置可以进一步含有添加剂如渗透促进剂或赋形剂，只要这些添加剂也不含酸官能团。 该装置可以是矩阵补丁或液体储存器补丁。 在基质贴剂中，载体是与类固醇药物紧密混合的生物相容的聚合物粘合剂。 粘合剂优选为丙烯酸类聚合物或共聚物。 在液体储存贴片中，载体是含有较薄或增稠剂的受控粘度组合物。 优选的类固醇药物包括某些皮质类固醇和性激素，如孕激素和雄激素。 还公开了在透皮贴剂储存期间稳定这种类固醇药物的方法。

公开(公告)号：US08951996B2

公开(公告)日：2015-02-10

申请号：US13193571

申请日：2011-07-28

Applicant: Chandrashekar Giliyar ,  Srinivasan Venkateshwaran ,  Basawaraj Chickmath ,  Satish Kumar Nachaegari ,  Chidambaram Nachiappan ,  Mahesh V. Patel

Inventor： Chandrashekar Giliyar ,  Srinivasan Venkateshwaran ,  Basawaraj Chickmath ,  Satish Kumar Nachaegari ,  Chidambaram Nachiappan ,  Mahesh V. Patel

IPC: A61K31/56 ,  A61K9/48 ,  A61K31/57 ,  A61K9/20 ,  A61K9/14 ,  A61K9/16

CPC classification number: A61K31/57 ,  A61K8/63 ,  A61K9/0053 ,  A61K9/14 ,  A61K9/145 ,  A61K9/1617 ,  A61K9/1623 ,  A61K9/1635 ,  A61K9/1641 ,  A61K9/1652 ,  A61K9/1676 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2031 ,  A61K9/2054 ,  A61K9/2059 ,  A61K9/4841 ,  A61K9/4858 ,  A61K9/4866 ,  A61K47/10 ,  A61K47/12 ,  A61K47/14 ,  A61K47/20 ,  A61K47/22 ,  A61K47/26 ,  A61K47/32 ,  A61K47/44 ,  A61K2800/10 ,  A61Q11/00

Abstract: The present invention provides for bioavailable oral dosage forms containing esters of 17-hydroxyprogesterone as well as related methods. The oral dosage forms can be formulated for pregnancy support and can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. In another embodiment, a pharmaceutically acceptable oral dosage form for pregnancy support is provided. The pharmaceutically acceptable oral dosage can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. The oral dosage form can, when measured using a USP Type-II dissolution apparatus in 900 mL of deionized water with 0.5 (w/v) of sodium lauryl sulfate at 50 RPM at 37° C., release at least 20 wt % of the dose of the ester of 17-hydroxyprogesterone after 60 minutes, or in the alternative release at least 20 wt % more after 60 minutes than an equivalently dosed oral dosage form without the carrier.

Abstract translation: 本发明提供含有17-羟孕酮酯的生物可利用的口服剂型以及相关方法。 口服剂型可以配制用于妊娠支持，并且可以包括治疗有效量的17-羟孕酮和药学上可接受的载体的酯。 在另一个实施方案中，提供了用于妊娠支持的药学上可接受的口服剂型。 药学上可接受的口服剂量可以包括治疗有效量的17-羟孕酮和可药用载体的酯。 口服剂型可以使用USP Type-II溶出装置在90mL的90RPM的90mL去离子水和0.5（w / v）十二烷基硫酸钠的条件下测量，在37℃下以50RPM释放至少20wt％ 60分钟后17-羟孕酮酯的剂量，或在替代释放中60分钟后至少20重量％比不含载体的等效给药口服剂型更多。

公开(公告)号：US20140377317A1

公开(公告)日：2014-12-25

申请号：US14477771

申请日：2014-09-04

Applicant: Chandrashekar Giliyar ,  Srinivasan Venkateshwaran ,  Basawaraj Chickmath ,  Satish Kumar Nachaegari ,  Chidambaram Nachiappan ,  Mahesh V. Patel

Inventor： Chandrashekar Giliyar ,  Srinivasan Venkateshwaran ,  Basawaraj Chickmath ,  Satish Kumar Nachaegari ,  Chidambaram Nachiappan ,  Mahesh V. Patel

IPC: A61K8/63 ,  A61Q11/00

CPC classification number: A61K31/57 ,  A61K8/63 ,  A61K9/0053 ,  A61K9/14 ,  A61K9/145 ,  A61K9/1617 ,  A61K9/1623 ,  A61K9/1635 ,  A61K9/1641 ,  A61K9/1652 ,  A61K9/1676 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2031 ,  A61K9/2054 ,  A61K9/2059 ,  A61K9/4841 ,  A61K9/4858 ,  A61K9/4866 ,  A61K47/10 ,  A61K47/12 ,  A61K47/14 ,  A61K47/20 ,  A61K47/22 ,  A61K47/26 ,  A61K47/32 ,  A61K47/44 ,  A61K2800/10 ,  A61Q11/00

Abstract: The present invention provides for bioavailable oral dosage forms containing esters of 17-hydroxyprogesterone as well as related methods. The oral dosage forms can be formulated for pregnancy support and can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. In another embodiment, a pharmaceutically acceptable oral dosage form for pregnancy support is provided. The pharmaceutically acceptable oral dosage can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. The oral dosage form can, when measured using a USP Type-II dissolution apparatus in 900 mL of deionized water with 0.5 (w/v) of sodium lauryl sulfate at 50 RPM at 37° C., release at least 20 wt % of the dose of the ester of 17-hydroxyprogesterone after 60 minutes, or in the alternative release at least 20 wt % more after 60 minutes than an equivalently dosed oral dosage form without the carrier.

Abstract translation: 本发明提供含有17-羟孕酮酯的生物可利用的口服剂型以及相关方法。 口服剂型可以配制用于妊娠支持，并且可以包括治疗有效量的17-羟孕酮和药学上可接受的载体的酯。 在另一个实施方案中，提供了用于妊娠支持的药学上可接受的口服剂型。 药学上可接受的口服剂量可以包括治疗有效量的17-羟孕酮和可药用载体的酯。 口服剂型可以使用USP Type-II溶出装置在90mL的90RPM的90mL去离子水和0.5（w / v）十二烷基硫酸钠的条件下，在37℃下以50RPM释放至少20wt％ 60分钟后17-羟孕酮酯的剂量，或在替代释放中60分钟后至少20重量％比不含载体的等效给药口服剂型更多。

公开(公告)号：US20110312928A1

公开(公告)日：2011-12-22

申请号：US13204562

申请日：2011-08-05

Applicant: Satish Kumar Nachaegari ,  Chandrashekar Giliyar ,  Chidambaram Nachiappan ,  Mahesh V. Patel ,  Srinivasan Venkateshwaran

Inventor： Satish Kumar Nachaegari ,  Chandrashekar Giliyar ,  Chidambaram Nachiappan ,  Mahesh V. Patel ,  Srinivasan Venkateshwaran

IPC: A61K31/57 ,  A61P15/00 ,  A61P15/18 ,  A61P15/16 ,  A61P35/00 ,  A61P19/10

CPC classification number: A61K31/57 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/2077 ,  A61K9/209 ,  A61K9/2846 ,  A61K9/4808 ,  A61K9/4858 ,  A61K9/4866

Abstract: The present invention provides for progesterone containing pharmaceutical oral dosage forms and related methods. The oral dosage forms can each include an amount of progesterone as well as a pharmaceutically acceptable carrier. The oral dosage forms can be formulated to have at least one of the following characteristics: the oral dosage form produces an pregnane metabolite mean blood plasma level of less than about 1000 nmol/L; the oral dosage form produces an pregnane metabolites mean blood plasma level, after administration of single dose of progesterone composition, such that the ratio of pregnane metabolite level to parent progesterone level of less than 10:1; has a dissolution rate in vitro, when measure using a USP Type-1 dissolution apparatus in 900 mL of deionized water with 2.0% (w/v) of sodium lauryl sulfate at 100 rpm, such that the oral dosage form releases at least 10 wt % of the progesterone within the first 30 minutes and/or releases less than 45 wt % in the first 4 hours; and the oral dosage form produces a ratio of mean plasma progesterone AUC to the amount of progesterone administered of more than 1.5×10−6 hr/mL:1.

Abstract translation: 本发明提供含有孕酮的药物口服剂型和相关方法。 口服剂型各自可以包含一定量的孕酮以及药学上可接受的载体。 口服剂型可以配制成具有以下特征中的至少一种：口服剂型产生的孕代谢物平均血浆水平低于约1000nmol / L; 口服剂型产生孕烷代谢物平均血浆水平，施用单次孕酮组合物后，孕妇代谢物水平与母体孕酮水平的比例小于10：1; 当使用USP1型溶出装置在900mL具有2.0％（w / v）月桂基硫酸钠的去离子水中以100rpm进行测量时，其体外溶出速率使得口服剂型释放至少10重量％ 在前30分钟内孕酮的百分比和/或在前4小时内释放小于45重量％ 并且口服剂型产生平均血浆孕酮AUC与施用孕酮量的比例大于1.5×10-6hr / mL：1。